RPL37P2: A Potential Drug Target and Biomarker for Neurodegenerative Diseases

Target Name: RPL37P2

NCBI ID: G116730

RPL37P2

Other Name(s): PSANK1 | RPL37_9_1150 | ribosomal protein L37 pseudogene 2 | Ribosomal protein L37 pseudogene 2

RPL37P2: A Potential Drug Target and Biomarker for Neurodegenerative Diseases

RPL37P2 (PSANK1) is a protein that is expressed in various tissues of the body, including the brain, heart, and blood vessels. It is a member of the P-type ATP-binding cassette (P-ABC) family, which is a subfamily of the superfamily of ATP-binding proteins known as the P-type ATPases (P-ATPases) or P-type Ca2+ channels. P-ATPases are involved in the regulation of cellular processes that are dependent on ATP, such as cell signaling, cytoskeletal organization, and chromatin remodeling.

The RPL37P2 gene is located on chromosome 11q22 and encodes a protein with 31 amino acid residues. The protein has a molecular weight of 41 kDa and a calculated pI of 6.9. RPL37P2 is predominantly expressed in the brain, with a significant expression in the heart and blood vessels.

Drug targeting RPL37P2

RPL37P2 is a potential drug target due to its involvement in various cellular processes that can be modulated by drugs. The ability of drugs to bind to RPL37P2 and modulate its activity could be useful in treating a variety of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and cardiovascular disease.

One approach to targeting RPL37P2 is to use small molecules that can bind to its extracellular domain. The extracellular domain of RPL37P2 consists of a single伪-helix, which is responsible for the protein's stability and functions as a binding protein. A variety of small molecules, including inhibitors of protein synthesis, have been shown to interact with RPL37P2 and modulate its activity.

Another approach to targeting RPL37P2 is to use antibodies that recognize its protein and can label it for imaging. This approach could be useful in studying the distribution and activity of RPL37P2 in different tissues and cells.

Biomarker potential

RPL37P2 may also be used as a biomarker for various neurodegenerative diseases. The decreased expression of RPL37P2 in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, has been observed, which may indicate a potential role for RPL37P2 in the development and progression of these diseases.

Additionally, the increased expression of RPL37P2 in certain neurodegenerative diseases, such as neurofibrillary tangles and senile plaques, may be an indication of the involvement of RPL37P2 in the pathophysiology of these diseases. Therefore, measuring the expression level of RPL37P2 could be a useful biomarker for the diagnosis and monitoring of neurodegenerative diseases.

Conclusion

RPL37P2 is a protein that is expressed in various tissues of the body and has been implicated in the regulation of various cellular processes. Its expression and activity have been modulated by various factors, including drugs and small molecules. Therefore, RPL37P2 is a potential drug target and biomarker for various neurodegenerative diseases. Further studies are needed to fully understand the role of RPL37P2 in these diseases and to develop effective treatments.

Protein Name: Ribosomal Protein L37 Pseudogene 2

The "RPL37P2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL37P2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets